非嚢胞性線維症性気管支拡張症（NCFB）の成人患者におけるネブライザーCSL787の用量範囲探索、有効性および安全性試験

基本情報

NCT ID

NCT07048262

ステータス

募集中

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

450

治験依頼者名

CSL Behring

概要

This study is a phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose range finding study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (immunoglobulin G \[IgG\] inhalation solution) compared with placebo over a period of 6 to 12 months independent of the occurrence of pulmonary exacerbations. The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 active treatment regimens of inhaled CSL787 administered to participants with NCFB toward prolonging the TTF exacerbation.

対象疾患

介入

依頼者（Sponsor）

実施施設 (10)